Rokeya Tasnin, MD
Psychiatry · Middletown, OHNPI 1285820001
Payments from drug & device makers
Across 1,069 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Axsome Therapeutics, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$1K
- plus $6K from 24 others
What the payments were for
- Food & beverage$14,95599%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 94 | $1,951 |
| AbbVie(2 entities) | 126 | $1,556 |
| Otsuka America Pharmaceutical, Inc. | 136 | $1,544 |
| Axsome Therapeutics, Inc. | 66 | $1,502 |
| Vanda Pharmaceuticals Inc. | 63 | $1,340 |
| Alkermes, Inc. | 133 | $1,255 |
| Teva Pharmaceuticals USA, Inc. | 93 | $1,249 |
| Lundbeck LLC | 60 | $812 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 61 | $774 |
| E.r. Squibb & Sons, L.L.C. | 59 | $734 |
| Neurocrine Biosciences, Inc. | 26 | $396 |
| Tris Pharma Inc | 35 | $315 |
| Supernus Pharmaceuticals, Inc. | 15 | $254 |
| Corium, LLC | 21 | $238 |
| Indivior Inc. | 15 | $232 |
| Sunovion Pharmaceuticals Inc. | 20 | $214 |
| Ironshore Pharmaceuticals Inc. | 9 | $146 |
| Almatica Pharma LLC | 6 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $99 |
| Novartis | 1 | $42 |
| Shire North American Group Inc | 3 | $39 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 2 | $28 |
| Biogen | 1 | $25 |
| Sage Therapeutics, LLC | 1 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
- INVEGA$125
- SPRAVATO$125
- Auvelity$122
How this compares
$15,034 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 118 | $170,256 |
| RexultiBrexpiprazole | 80 | $116,876 |
| AristadaAripiprazole Lauroxil | 14 | $46,376 |
| Abilify MaintenaAripiprazole | 13 | $36,197 |
| PerserisRisperidone | 15 | $36,101 |
| FanaptIloperidone | 12 | $34,469 |
| AuvelityDextromethorphan Hbr/Bupropion | 23 | $28,786 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $22,976 |
| TrintellixVortioxetine Hydrobromide | 27 | $16,731 |
| Lurasidone Hcl | 50 | $7,084 |
| Dyanavel XrAmphetamine | 16 | $6,949 |
| FetzimaLevomilnacipran Hcl | 14 | $6,858 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 78 | $5,653 |
| QuviviqDaridorexant Hcl | 11 | $5,386 |
| Aripiprazole | 70 | $4,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,556 | $177,114132 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,544 | $153,07493 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,255 | $69,35129 claims |
| Indivior Inc.Perseris | $232 | $36,10115 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,340 | $34,46912 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,502 | $28,78623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $99 | $16,73127 claims |
| Tris Pharma IncDyanavel Xr | $315 | $6,94916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Middletown
- Emad AlshamiMiddletown$98K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.